Clinical Trials Browser

Interventional × Gastro-enteropancreatic neuroendocrine tumor × 1 year × Clear all

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell, Somatostatinoma, Carcinoma, Adenosquamous

NCT06784752 2026-03-06

NETTER-3

Phase 3 Recruiting

240 enrolled

EndocrineGastrointestinalLymphoidNET

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Follicular

NCT03833700 2026-02-27

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Phase 1 Active not recruiting

70 enrolled

EndocrineGastrointestinalNETSarcoma

Gastro-enteropancreatic neuroendocrine tumor, Digestive System Neoplasms, Carcinoma, Hepatocellular, Colorectal Neoplasms, Desmoid Tumors, Adrenocortical Carcinoma

NCT04711135 2026-02-12

NETTER-P

Phase 2 Active not recruiting

11 enrolled 14 charts 1 FDA

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT03972488 2026-01-21

NETTER-2

Phase 3 Active not recruiting

226 enrolled 14 charts

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT04505553 2026-01-21

Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer

Phase 2 Completed

78 enrolled 14 charts

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Anus Neoplasms, Appendiceal Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Adenoma, Islet Cell, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT05477576 2026-01-20

ACTION-1

Phase 3 Recruiting

288 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03891784 2026-01-14

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

Phase 2 Active not recruiting

20 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell

NCT05987176 2026-01-14

NELMAS

Phase 2 Terminated

1 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT06441331 2025-12-17

KinLET

Phase 1 Recruiting

20 enrolled

CNSEndocrineGastrointestinalLymphoidNETSarcoma

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroendocrine Tumors

NCT05636618 2025-11-24

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors

Phase 1/2 Recruiting

260 enrolled

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT05050942 2025-11-06

SORENTO

Phase 3 Active not recruiting

332 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT06790706 2025-10-06

IMMUNORARE5

Phase 2 Recruiting

154 enrolled

EndocrineGastrointestinalGynecologicHead & NeckNETThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Thymoma, Gestational Trophoblastic Disease, Thyroid Carcinoma, Anaplastic

NCT06256705 2025-09-22

OPERANDI-NET

Phase NA Recruiting

80 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT04919226 2025-09-10

COMPOSE

Phase 3 Active not recruiting

259 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT07165132 2025-09-10

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Phase 1 Not yet recruiting

104 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT04609592 2025-09-09

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Phase 1 Recruiting

10 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT05385861 2025-08-15

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

Phase 1/2 Enrolling by invitation

52 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT05262556 2025-08-07

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Phase 1 Active not recruiting

15 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine

NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Phase 1/2 Completed

316 enrolled

CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

Clinical Trials

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

NETTER-3

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

NETTER-P

NETTER-2

Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer

ACTION-1

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

NELMAS

KinLET

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors

SORENTO

IMMUNORARE5

OPERANDI-NET

COMPOSE

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors